newsfilter
← Latest News
GlobeNewswire·

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

  • CorMedix Therapeutics will report Q4 and full-year 2025 financial results before the market opens on March 5, 2026.
  • A corporate update conference call is scheduled for 8:30am ET on March 5, 2026, with domestic, international, \& webcast access provided.
  • The company commercializes DefenCath for preventing catheter-related bloodstream infections in adult hemodialysis patients.
  • Following its August 2025 acquisition of Melinta Therapeutics, CorMedix markets anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, \& TOPROL-XL.
  • Ongoing clinical studies for DefenCath are targeting Total Parenteral Nutrition \& pediatric hemodialysis populations.
  • REZZAYO is approved for treating candidemia \& invasive candidiasis in adults.
  • A Phase III study for REZZAYO prophylaxis in adult allogeneic BMT patients is underway, with topline results expected in Q2 2026.